PF-07321332

URI: https://gptkb.org/entity/PF-07321332

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound antiviral drug
gptkbp:approvalYear	2021
gptkbp:approvedBy	gptkb:FDA
gptkbp:ATCCode	J05AE10
gptkbp:brand	gptkb:Nirmatrelvir
gptkbp:CASNumber	gptkb:2628280-40-8
gptkbp:category	antiviral drug investigational drug COVID-19 drug
gptkbp:clinicalTrialPhase	Phase 3
gptkbp:combines	gptkb:ritonavir
gptkbp:developedBy	gptkb:Pfizer
gptkbp:drugClass	protease inhibitor
gptkbp:firstDescribed	2021
gptkbp:hasMolecularFormula	C23H32F3N5O4
gptkbp:hasSMILES	CC1=NC(CN(C1=O)C2CC2)(C3=CC=CC=C3)C(=O)N4CCC(CC4)NC(=O)C(C(C)C)NC(=O)C(F)(F)F
https://www.w3.org/2000/01/rdf-schema#label	PF-07321332
gptkbp:indication	gptkb:COVID-19
gptkbp:IUPACName	(1R,2S,5S)-N-((1S)-1-cyano-2-((3S)-2-oxo-1,2,3,4-tetrahydro-1,3,4-oxadiazepin-3-yl)ethyl)-3-((2,2,2-trifluoroacetyl)amino)-4,4-dimethyl-2-oxopentanamide
gptkbp:legalStatus	prescription only
gptkbp:marketedAs	gptkb:Paxlovid
gptkbp:mechanismOfAction	SARS-CoV-2 main protease inhibitor
gptkbp:molecularWeight	499.5 g/mol
gptkbp:pregnancyCategory	Not assigned (US)
gptkbp:PubChem_CID	155903259
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	nausea vomiting diarrhea headache hypertension allergic reactions myalgia dysgeusia
gptkbp:target	gptkb:SARS-CoV-2_3CL_protease
gptkbp:UNII	QHU4B1DV9N
gptkbp:bfsParent	gptkb:nirmatrelvir
gptkbp:bfsLayer	6